The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience.
Saved in:
| Title: | The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience. |
|---|---|
| Authors: | Sim, V.1 (AUTHOR), Forner, S.1 (AUTHOR), Burcombe, R.1 (AUTHOR), Glendenning, J.1 (AUTHOR) |
| Source: | Clinical Oncology. Jul2019, Vol. 31 Issue 7, pe114-e114. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
